• Search
  • Advanced Search

Review

September 27, 2021


The role of transjugular intrahepatic portosystemic shunt in patients with portal hypertension: Advantages and pitfalls
Hae Lim Lee, Sung Won Lee
Clin Mol Hepatol. 2022;28(2):121-134.

Transjugular intrahepatic portosystemic shunt (TIPS) is an effective interventional procedure to relieve portal hypertension, which is a main mechanism for the development of complications of liver cirrhosis (LC), such as...

Review

October 22, 2021


Approaches to quantifying hepatitis B virus covalently closed circular DNA
Henrik Zhang, Thomas Tu
Clin Mol Hepatol. 2022;28(2):135-149.

Chronic hepatitis B is a major cause of liver disease worldwide and is currently incurable. Hepatitis B virus (HBV) covalently closed circular (ccc) DNA is a key form of the...

Review

November 10, 2021


MAFLD enhances clinical practice for liver disease in the Asia-Pacific region
Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, et al.
Clin Mol Hepatol. 2022;28(2):150-163.

Fatty liver is now a major cause of liver disease in the Asia-Pacific region. Liver diseases in this region have distinctive characteristics. First, fatty liver is frequently observed in lean/normal-weight...

Review

December 27, 2021


Cost-effectiveness of chronic hepatitis C screening and treatment
Hye Won Lee, Hankil Lee, Beom Kyung Kim, et al.
Clin Mol Hepatol. 2022;28(2):164-173.

Hepatitis C virus (HCV) infection is the second most common cause of chronic liver disease in South Korea, with a prevalence ranging from 0.6% to 0.8%, and HCV infection incidence...

Original Article

November 28, 2021


Protective association of Klotho rs495392 gene polymorphism against hepatic steatosis in non-alcoholic fatty liver disease patients
Wen-Yue Liu, Xiaofang Zhang, Gang Li, et al.
Clin Mol Hepatol. 2022;28(2):183-195.

Background/Aims: Non-alcoholic fatty liver disease (NAFLD) is closely associated with metabolic dysfunction. Among the multiple factors, genetic variation acts as important modifiers. Klotho, an enzyme encoded by the klotho (KL)...

Original Article

January 13, 2022


Prevalence trends of non-alcoholic fatty liver disease among young men in Korea: A Korean military population-based cross-sectional study
Jaejun Lee, Taeyun Kim, Hyun Yang, et al.
Clin Mol Hepatol. 2022;28(2):196-206.

Background/Aims: Non-alcoholic fatty liver disease (NAFLD) has become a major concern in Korea since its emergence as a dominant cause of chronic liver disease. However, no study has explored its...

Original Article

November 24, 2021


Surgery versus radiofrequency ablation in patients with Child- Pugh class-A/single small (≤3 cm) hepatocellular carcinoma
Jungnam Lee, Young-Joo Jin, Seung Kak Shin, et al.
Clin Mol Hepatol. 2022;28(2):207-218.
Background/Aims: We compared the post-treatment overall survival (OS) and recurrence-free survival (RFS) between patients with Child-Turcotte-Pugh (CTP) class-A and single small (≤3 cm) hepatocellular carcinoma (HCC) treated by surgical resection...

Original Article

July 20, 2021


Association between serum tumor necrosis factor-α and sarcopenia in liver cirrhosis
Ji Won Han, Da In Kim, Hee Chul Nam, et al.
Clin Mol Hepatol. 2022;28(2):219-231.

Background/Aims: Sarcopenia is an independent prognostic factor of liver cirrhosis (LC). However, the association between LC-related systemic inflammation and sarcopenia is unclear. Methods: Sprague-Dawley rats were treated with thioacetamide (TAA) or...

Original Article

January 5, 2022


Galectin-3 inhibits cardiac contractility via a tumor necrosis factor alpha-dependent mechanism in cirrhotic rats
Ki Tae Yoon, Hongqun Liu, Jing Zhang, et al.
Clin Mol Hepatol. 2022;28(2):232-241.

Background/Aims: Galectin-3 plays a key pathogenic role in cardiac hypertrophy and heart failure. The present study aimed to investigate the effects of galectin-3 on cardiomyopathy – related factors and cardiac...

Original Article

February 7, 2022


Cause of death and cause-specific mortality for primary liver cancer in South Korea: A nationwide population-based study in hepatitis B virus-endemic area
Bo Hyun Kim, Dahhay Lee, Kyu-Won Jung, et al.
Clin Mol Hepatol. 2022;28(2):242-253.

Background/Aims: Primary liver cancer is one of the leading causes of cancer mortality worldwide. However, the causes of death have not been studied in detail in patients with liver cancer. Methods:...

Original Article

December 28, 2021


Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis
Joonho Jeong, Jung Woo Shin, Seok Won Jung, et al.
Clin Mol Hepatol. 2022;28(2):254-264.
Background/Aims: Tenofovir alafenamide (TAF) has shown less favorable effect on lipids compared to tenofovir disoproxil fumarate (TDF) in clinical trials. However, data regarding these outcomes in patients with chronic hepatitis...
Current Issue
Volume 28(2); Apr 2022
Review
1636
The role of transjugular intrahepatic portosystemic shunt in patients with portal hypertension: Advantages and pitfalls
Hae Lim Lee, Sung Won Lee
Clin Mol Hepatol. 2022;28(2):121-134.   Published online September 27, 2021
View: 1604   Download: 187
1641
Approaches to quantifying hepatitis B virus covalently closed circular DNA
Henrik Zhang, Thomas Tu
Clin Mol Hepatol. 2022;28(2):135-149.   Published online October 22, 2021
View: 1951   Download: 173
1644
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region
Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura
Clin Mol Hepatol. 2022;28(2):150-163.   Published online November 10, 2021
View: 1408   Download: 179  Citations: 4
1652
Cost-effectiveness of chronic hepatitis C screening and treatment
Hye Won Lee, Hankil Lee, Beom Kyung Kim, Young Chang, Jae Young Jang, Do Young Kim
Clin Mol Hepatol. 2022;28(2):164-173.   Published online December 27, 2021
View: 1010   Download: 80
Editorial
Surgical resection versus ablation for early hepatocellular carcinoma: The debate is still open
Bo Hyun Kim
Clin Mol Hepatol. 2022;28(2):174-176.   Published online January 26, 2022
View: 668   Download: 47
1628
Leaky gut-derived tumor necrosis factor-α causes sarcopenia in patients with liver cirrhosis
Takumi Kawaguchi, Takuji Torimura
Clin Mol Hepatol. 2022;28(2):177-180.   Published online August 26, 2021
View: 1240   Download: 81
Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles
Hung-Yao Lin, Tai-Chung Tseng
Clin Mol Hepatol. 2022;28(2):181-182.   Published online February 21, 2022
View: 661   Download: 54
Original Article
1648
Protective association of Klotho rs495392 gene polymorphism against hepatic steatosis in non-alcoholic fatty liver disease patients
Wen-Yue Liu, Xiaofang Zhang, Gang Li, Liang-Jie Tang, Pei-Wu Zhu, Rafael S. Rios, Kenneth I. Zheng, Hong-Lei Ma, Xiao-Dong Wang, Qiuwei Pan, Robert J. de Knegt, Luca Valenti, Mohsen Ghanbari, Ming-Hua Zheng
Clin Mol Hepatol. 2022;28(2):183-195.   Published online November 28, 2021
View: 1237   Download: 120
1656
Prevalence trends of non-alcoholic fatty liver disease among young men in Korea: A Korean military population-based cross-sectional study
Jaejun Lee, Taeyun Kim, Hyun Yang, Si Hyun Bae
Clin Mol Hepatol. 2022;28(2):196-206.   Published online January 13, 2022
View: 1049   Download: 94
Surgery versus radiofrequency ablation in patients with Child- Pugh class-A/single small (≤3 cm) hepatocellular carcinoma
Jungnam Lee, Young-Joo Jin, Seung Kak Shin, Jung Hyun Kwon, Sang Gyune Kim, Young Ju Suh, Yujin Jeong, Jung Hwan Yu, Jin-Woo Lee, Oh Sang Kwon, Soon Woo Nahm, Young Seok Kim
Clin Mol Hepatol. 2022;28(2):207-218.   Published online November 24, 2021
View: 1177   Download: 122  Citation: 1
1623
Association between serum tumor necrosis factor-α and sarcopenia in liver cirrhosis
Ji Won Han, Da In Kim, Hee Chul Nam, U Im Chang, Jin Mo Yang, Do Seon Song
Clin Mol Hepatol. 2022;28(2):219-231.   Published online July 20, 2021
View: 14257   Download: 185  Citations: 3
1655
Galectin-3 inhibits cardiac contractility via a tumor necrosis factor alpha-dependent mechanism in cirrhotic rats
Ki Tae Yoon, Hongqun Liu, Jing Zhang, Sojung Han, Samuel S. Lee
Clin Mol Hepatol. 2022;28(2):232-241.   Published online January 5, 2022
View: 983   Download: 47  Citation: 1
1661
Cause of death and cause-specific mortality for primary liver cancer in South Korea: A nationwide population-based study in hepatitis B virus-endemic area
Bo Hyun Kim, Dahhay Lee, Kyu-Won Jung, Young-Joo Won, Hyunsoon Cho
Clin Mol Hepatol. 2022;28(2):242-253.   Published online February 7, 2022
View: 763   Download: 48
Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis
Joonho Jeong, Jung Woo Shin, Seok Won Jung, Eun Ji Park, Neung Hwa Park
Clin Mol Hepatol. 2022;28(2):254-264.   Published online December 28, 2021
View: 1066   Download: 151  Citation: 1
Letter to the Editor
Letter: cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis
Yi-Chun Huang, Chih-Wei Chen, James Chun-Chung Wei
Clin Mol Hepatol. 2022;28(2):265-266.   Published online January 4, 2022
View: 3938   Download: 22  Citation: 1
Reply: Letter: cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis
Jihyun An, Ju Hyun Shim
Clin Mol Hepatol. 2022;28(2):267-268.   Published online January 18, 2022
View: 633   Download: 23
Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs
Saori Takamura, Yuichi Teraki, Eri Katayama, Takumi Kawaguchi, Machiko Kawaguchi, Dan Nakano, Tsubasa Tsutsumi, Sumiko Nagoshi, Takekuni Nakama, Takuji Torimura
Clin Mol Hepatol. 2022;28(2):269-272.   Published online February 15, 2022
View: 863   Download: 149
Snapshot
1662
Acute on chronic liver failure in cirrhosis
Marta Tonon, Salvatore Piano
Clin Mol Hepatol. 2022;28(2):273-275.   Published online February 14, 2022
View: 662   Download: 57
Guideline
KASL clinical practice guidelines for management of chronic hepatitis B
Clin Mol Hepatol. 2022;28(2):276-331.   Published online April 1, 2022
View: 1236   Download: 148  Citation: 1

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

  • PubMed Central
  • PubMed
  • Scopus
  • KoreaMed
  • KoMCI
  • ScienceCentral
  • DOAJ
  • GoogleScholar
  • Similarity Check
  • Crossref Cited-by Linking
  • CrossMark
  • Funder Registry
  • Metadata
  • ORCID
  • MeSH on Demand
  • COPE
  • EMBASE
  • KOFST
  • ICMJE
  • Web of SCIENCE
ABOUT
BROWSE ARTICLES
CURRENT ISSUE
FOR CONTRIBUTORS
Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 690
TOTAL : 829149
Close layer